Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 14

1.

Pharmacogenetic testing affects choice of therapy among women considering tamoxifen treatment.

Lorizio W, Rugo H, Beattie MS, Tchu S, Melese T, Melisko M, Wu AH, Lawrence HJ, Nikoloff M, Ziv E.

Genome Med. 2011 Oct 4;3(10):64. doi: 10.1186/gm280.

PMID:
21970596
[PubMed]
Free PMC Article
2.

The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review.

Fleeman N, Martin Saborido C, Payne K, Boland A, Dickson R, Dundar Y, Fernández Santander A, Howell S, Newman W, Oyee J, Walley T.

Health Technol Assess. 2011 Sep;15(33):1-102. doi: 10.3310/hta15330. Review.

PMID:
21906462
[PubMed - indexed for MEDLINE]
Free Article
3.

The AmpliChip CYP450 genotyping test: Integrating a new clinical tool.

de Leon J, Susce MT, Murray-Carmichael E.

Mol Diagn Ther. 2006;10(3):135-51. Review.

PMID:
16771600
[PubMed - indexed for MEDLINE]
4.

Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19.

de Leon J, Armstrong SC, Cozza KL.

Psychosomatics. 2006 Jan-Feb;47(1):75-85. Review.

PMID:
16384813
[PubMed - indexed for MEDLINE]
5.

Impact of CYP2D*6 in the adjuvant treatment of breast cancer patients with tamoxifen.

Markopoulos C, Kykalos S, Mantas D.

World J Clin Oncol. 2014 Aug 10;5(3):374-81. doi: 10.5306/wjco.v5.i3.374. Review.

PMID:
25114852
[PubMed]
Free PMC Article
6.

CYP2D6 genotype and tamoxifen response for breast cancer: a systematic review and meta-analysis.

Lum DW, Perel P, Hingorani AD, Holmes MV.

PLoS One. 2013 Oct 2;8(10):e76648. doi: 10.1371/journal.pone.0076648. eCollection 2013. Review.

PMID:
24098545
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Towards the implementation of CYP2D6 and CYP2C19 genotypes in clinical practice: update and report from a pharmacogenetic service clinic.

Müller DJ, Kekin I, Kao AC, Brandl EJ.

Int Rev Psychiatry. 2013 Oct;25(5):554-71. doi: 10.3109/09540261.2013.838944. Review.

PMID:
24151801
[PubMed - indexed for MEDLINE]
8.

Pharmacogenetics of tamoxifen: who should undergo CYP2D6 genetic testing?

Higgins MJ, Rae JM, Flockhart DA, Hayes DF, Stearns V.

J Natl Compr Canc Netw. 2009 Feb;7(2):203-13. Review.

PMID:
19200418
[PubMed - indexed for MEDLINE]
9.

Clinical implications of CYP2D6 genotyping in tamoxifen treatment for breast cancer.

Dezentjé VO, Guchelaar HJ, Nortier JW, van de Velde CJ, Gelderblom H.

Clin Cancer Res. 2009 Jan 1;15(1):15-21. doi: 10.1158/1078-0432.CCR-08-2006. Review.

PMID:
19118028
[PubMed - indexed for MEDLINE]
Free Article
10.

CYP2D6 polymorphisms and the impact on tamoxifen therapy.

Beverage JN, Sissung TM, Sion AM, Danesi R, Figg WD.

J Pharm Sci. 2007 Sep;96(9):2224-31. Review.

PMID:
17518364
[PubMed - indexed for MEDLINE]
11.

Impact of CYP2D6 polymorphism on tamoxifen therapy: where are we?

Huber-Wechselberger AE, Niedetzky P, Aigner I, Haschke-Becher E.

Wien Med Wochenschr. 2012 Jun;162(11-12):252-61. doi: 10.1007/s10354-012-0118-8. Epub 2012 Jun 12. Review.

PMID:
22688624
[PubMed - indexed for MEDLINE]
12.

Tamoxifen, cytochrome P450 genes and breast cancer clinical outcomes.

Singh MS, Francis PA, Michael M.

Breast. 2011 Apr;20(2):111-8. doi: 10.1016/j.breast.2010.11.003. Epub 2010 Dec 24. Review.

PMID:
21185724
[PubMed - indexed for MEDLINE]
13.

Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.

Zhou SF.

Clin Pharmacokinet. 2009;48(11):689-723. doi: 10.2165/11318030-000000000-00000. Review.

PMID:
19817501
[PubMed - indexed for MEDLINE]
14.

CYP2D6 and tamoxifen: DNA matters in breast cancer.

Hoskins JM, Carey LA, McLeod HL.

Nat Rev Cancer. 2009 Aug;9(8):576-86. doi: 10.1038/nrc2683. Review.

PMID:
19629072
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk